-DOCSTART-	O

Title	O
:	O
Heart	O
rate	O
variability	O
and	O
QT	O
dispersion	O
in	O
patients	B-P
with	I-P
subclinical	I-P
hypothyroidism	I-P
.	O

The	O
effect	O
of	O
subclinical	O
hypothyroidism	O
(	O
SH	O
)	O
on	O
cardiovascular	O
autonomic	O
function	O
and	O
ventricular	O
repolarization	O
has	O
not	O
been	O
yet	O
elucidated	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
dispersion	O
of	O
QT	O
interval	O
,	O
i	O
.	O
e	O
.	O
an	O
index	O
of	O
inhomogeneity	O
of	O
repolarization	O
,	O
and	O
heart	O
rate	O
variability	O
(	O
HRV	O
)	O
,	O
i	O
.	O
e	O
.	O
a	O
measure	O
of	O
cardiac	O
autonomic	O
modulation	O
,	O
in	O
SH	O
patients	O
.	O

METHODS	O
:	O
The	O
study	O
included	O
42	B-P
patients	I-P
(	I-P
29	I-P
women	I-P
and	I-P
13	I-P
men	I-P
;	I-P
mean	I-P
age	I-P
53	I-P
.	I-P
2	I-P
+	I-P
/	I-P
-	I-P
14	I-P
.	I-P

2	I-P
years	I-P
;	I-P
body	I-P
surface	I-P
area	I-P
1	I-P
.	I-P
76	I-P
+	I-P
/	I-P
-	I-P
0	I-P
.	I-P

14	I-P
m2	I-P
)	I-P
with	I-P
SH	I-P
,	I-P
as	I-P
judged	I-P
by	I-P
elevated	I-P
serum	I-P
TSH	I-P
levels	I-P
(	I-P
>	I-P
3	I-P
.	I-P
6	I-P
mIU	I-P
/	I-P
l	I-P
;	I-P
range	I-P
,	I-P
3	I-P
.	I-P
8	I-P
-	I-P
12	I-P
.	I-P

0	I-P
)	I-P
and	I-P
normal	I-P
free	I-P
thyroid	I-P
hormones	I-P
(	I-P
FT4	I-P
and	I-P
FT3	I-P
)	I-P
and	I-P
30	I-P
euthyroid	I-P
volunteer	I-P
.	O

Subjects	O
with	O
cardiac	O
,	O
metabolic	O
,	O
neurological	O
disease	O
or	O
any	O
other	O
systemic	O
disease	O
that	O
could	O
affect	O
autonomic	O
activity	O
were	O
excluded	O
from	O
the	O
study	O
.	O

Patients	O
with	O
SH	O
and	O
control	O
subjects	O
underwent	O
a	O
full	O
history	O
,	O
physical	O
examination	O
,	O
standard	O
12	O
-	O
lead	O
ECG	O
,	O
and	O
24	O
-	O
h	O
ambulatory	O
ECG	O
monitoring	O
.	O

To	O
evaluate	O
the	O
effect	O
of	O
treatment	O
with	O
L	O
-	B-I
thyroxine	I-I
on	O
QT	B-O
dispersion	I-O
and	O
HRV	B-O
,	O
15	O
patients	O
with	O
SH	O
were	O
randomly	O
assigned	O
to	O
receive	O
therapy	O
with	O
L	B-I
-	I-I
thyroxine	I-I
.	O

All	O
the	O
subjects	O
were	O
evaluated	O
at	O
enrolment	O
and	O
after	O
6	O
months	O
.	O

-DOCSTART-	O

Title	O
:	O
Virtual	B-I
reality	I-I
exposure	I-I
therapy	I-I
and	O
standard	B-C
(	I-C
in	I-C
vivo	I-C
)	I-C
exposure	I-C
therapy	I-C
in	O
the	O
treatment	O
of	O
fear	O
of	O
flying	O
.	O

METHODS	O
:	O
Eighty	B-P
-	I-P
three	I-P
participants	I-P
with	I-P
FOF	I-P
were	O
randomly	O
assigned	O
to	O
VRE	B-I
,	O
SE	B-C
,	O
or	O
WL	O
.	O

Seventy	O
-	O
five	O
participants	O
,	O
25	O
per	O
group	O
,	O
completed	O
the	O
study	O
.	O

Twenty	O
-	O
three	O
WL	O
participants	O
completed	O
randomly	O
assigned	O
treatment	O
following	O
the	O
waiting	O
period	O
.	O

Treatment	O
consisted	O
of	O
4	B-I
sessions	I-I
of	I-I
anxiety	I-I
management	I-I
training	I-I
followed	O
either	O
by	O
exposure	B-I
to	I-I
a	I-I
virtual	I-I
airplane	I-I
(	I-I
VRE	I-I
)	I-I
or	O
an	B-C
actual	I-C
airplane	I-C
at	I-C
the	I-C
airport	I-C
(	I-C
SE	I-C
)	I-C
conducted	O
over	O
6	O
weeks	O
.	O

-DOCSTART-	O

Title	O
:	O
Nordic	B-I
walking	I-I
and	O
chronic	O
low	O
back	O
pain	O
:	O
design	O
of	O
a	O
randomized	O
clinical	O
trial	O
.	O

METHODS	O
:	O
One	B-P
hundred	I-P
and	I-P
fifty	I-P
patients	I-P
with	I-P
low	I-P
back	I-P
pain	I-P
for	I-P
at	I-P
least	I-P
eight	I-P
weeks	I-P
and	I-P
referred	I-P
to	I-P
a	I-P
specialized	I-P
secondary	I-P
sector	I-P
outpatient	I-P
back	I-P
pain	I-P
clinic	I-P
are	O
included	O
in	O
the	O
study	O
.	O

After	O
completion	O
of	O
the	O
standard	O
back	O
centre	O
treatment	O
patients	O
are	O
randomized	O
into	O
one	O
of	O
three	O
groups	O
:	O
A	O
)	O
Nordic	B-I
Walking	I-I
twice	O
a	O
week	O
for	O
eight	O
weeks	O
under	O
supervision	O
of	O
a	O
specially	O
trained	O
instructor	O
;	O
B	O
)	O
Unsupervised	B-I
Nordic	I-I
Walking	I-I
for	O
eight	O
weeks	O
after	O
one	O
training	O
session	O
with	O
an	O
instructor	O
;	O
C	O
)	O
A	B-I
one	I-I
hour	I-I
motivational	I-I
talk	I-I
including	O
advice	O
to	O
stay	O
active	O
.	O

Outcome	O
measures	O
are	O
pain	B-O
,	O
function	B-O
,	O
overall	B-O
health	I-O
,	O
cardiovascular	B-O
ability	I-O
and	O
activity	B-O
level	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Endocrine	O
response	O
to	O
cataract	B-I
surgery	I-I
under	I-I
total	I-I
intravenous	I-I
anaesthesia	I-I
,	O
local	B-I
anaesthesia	I-I
under	I-I
sedation	I-I
or	O
local	B-I
anaesthesia	I-I
alone	I-I
:	O
a	O
comparative	O
study	O
.	O

-DOCSTART-	O

Title	O
:	O
Evolution	O
of	O
neuropathy	O
and	O
myopathy	O
during	O
intensive	B-I
vincristine	I-I
/	O
corticosteroid	B-I
chemotherapy	I-I
for	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
.	O

METHODS	O
:	O
In	O
this	O
study	O
,	O
vincristine	B-I
was	O
administered	O
by	O
bolus	O
injection	O
followed	O
by	O
a	O
3	O
-	O
day	O
continuous	O
intravenous	O
(	O
IV	O
)	O
infusion	O
(	O
total	O
dose	O
of	O
2	O
.	O
0	O
mg	O
/	O
m2	O
every	O
other	O
week	O
)	O
;	O
the	O
maximum	O
dose	O
of	O
vincristine	B-I
was	O
not	O
arbitrarily	O
limited	O
.	O

Cronassial	B-I
,	O
a	O
mixture	O
of	O
four	O
naturally	O
occurring	O
gangliosides	O
,	O
was	O
administered	O
in	O
a	O
randomized	O
double	O
-	O
blind	O
test	O
to	O
evaluate	O
whether	O
this	O
agent	O
could	O
prevent	O
vincristine	B-O
-	I-O
induced	I-O
neuropathy	I-O
.	O

High	B-I
doses	I-I
of	I-I
dexamethasone	I-I
(	O
50	O
mg	O
/	O
d	O
for	O
3	O
days	O
weekly	O
or	O
every	O
other	O
week	O
)	O
were	O
also	O
prescribed	O
.	O

Patients	O
were	O
monitored	O
every	O
4	O
weeks	O
with	O
comprehensive	B-O
physical	I-O
and	O
neurologic	B-O
examinations	I-O
and	O
electrophysiologic	B-O
studies	I-O
of	I-O
peripheral	I-O
nerve	I-O
function	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Polydioxanone	B-I
sternal	I-I
sutures	I-I
for	O
prevention	O
of	O
sternal	O
dehiscence	O
.	O

METHODS	O
:	O
Three	B-P
hundred	I-P
sixty	I-P
-	I-P
six	I-P
patients	I-P
undergoing	I-P
elective	I-P
cardiac	I-P
surgery	I-P
with	I-P
full	I-P
median	I-P
sternotomy	I-P
and	I-P
having	I-P
body	I-P
surface	I-P
area	I-P
(	I-P
BSA	I-P
)	I-P
less	I-P
than	I-P
1	I-P
.	I-P
5	I-P
m	I-P
(	I-P
2	I-P
)	I-P
were	O
randomly	O
assigned	O
to	O
receive	O
PDS	B-I
(	O
n	O
=	O
181	O
)	O
or	O
stainless	B-C
steel	I-C
(	I-C
SS	I-C
,	I-C
n	I-C
=	I-C
185	I-C
)	I-C
sternal	I-C
approximation	I-C
.	O

The	O
study	O
was	O
focused	O
on	O
aseptic	O
sternal	O
complications	O
,	O
namely	O
bone	B-O
dehiscence	I-O
and	O
superficial	B-O
wound	I-O
instability	I-O
.	O

-DOCSTART-	O

Title	O
:	O
B	B-I
-	I-I
vitamins	I-I
reduce	O
plasma	O
levels	O
of	O
beta	O
amyloid	O
.	O

METHODS	O
:	O
We	O
randomized	O
299	B-P
older	I-P
men	I-P
to	O
treatment	O
with	O
2mg	B-I
of	I-I
folate	I-I
,	O
plus	O
25mg	B-I
of	I-I
B6	I-I
and	O
400	B-I
microg	I-I
of	I-I
B12	I-I
,	O
or	O
placebo	B-C
.	O

-DOCSTART-	O

Title	O
:	O
A	O
randomized	O
controlled	O
trial	O
to	O
evaluate	O
the	O
efficacy	O
of	O
ultrasound	B-I
-	I-I
guided	I-I
laser	I-I
photocoagulation	I-I
for	O
treatment	O
of	O
benign	O
thyroid	O
nodules	O
.	O

METHODS	O
:	O
Twenty	B-P
six	I-P
subjects	I-P
were	O
randomized	O
to	O
the	O
intervention	O
(	O
no	O
.	O

13	O
,	O
age	O
68	O
+	O
/	O
-	O
3	O
yr	O
,	O
mean	O
+	O
/	O
-	O
SEM	O
)	O
or	O
observation	B-C
(	O
no	O
.	O

13	O
,	O
age	O
71	O
+	O
/	O
-	O
2	O
yr	O
)	O
groups	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
effects	O
of	O
chewing	B-I
versus	O
caffeine	B-I
on	O
alertness	O
,	O
cognitive	O
performance	O
and	O
cardiac	O
autonomic	O
activity	O
during	O
sleep	O
deprivation	O
.	O

METHODS	O
:	O
Fourteen	B-P
adults	I-P
participated	O
in	O
a	O
randomized	O
,	O
counterbalanced	O
protocol	O
employing	O
a	B-I
chewing	I-I
,	O
placebo	B-C
and	O
caffeine	B-I
condition	I-I
.	O

Participants	O
completed	O
tasks	O
assessing	O
psychomotor	B-O
vigilance	I-O
,	O
tracking	B-O
,	O
grammatical	B-O
reasoning	I-O
,	O
alertness	B-O
and	O
sleepiness	B-O
each	I-O
hour	I-O
across	I-O
the	I-O
night	I-O
.	O

All	O
participants	O
received	O
either	O
placebo	B-C
or	O
caffeine	B-I
(	O
200	O
mg	O
)	O
,	O
while	O
the	B-I
chewing	I-I
condition	I-I
also	O
chewed	O
on	O
a	O
tasteless	O
and	O
odorless	O
substance	O
for	O
15	O
min	O
each	O
hour	O
.	O

Heart	B-O
rate	I-O
(	I-O
HR	I-O
)	I-O
,	O
root	B-O
mean	I-O
square	I-O
of	I-O
the	I-O
successive	I-O
differences	I-O
in	I-O
R	I-O
-	I-O
R	I-O
intervals	I-O
on	I-O
the	I-O
ECG	I-O
(	I-O
RMSSD	I-O
)	I-O
,	O
and	O
preejection	B-O
period	I-O
(	I-O
PEP	I-O
)	I-O
were	O
simultaneously	O
recorded	O
.	O

-DOCSTART-	O

Title	O
:	O
Impact	O
of	O
disease	B-I
severity	I-I
on	O
outcome	O
of	O
antiviral	O
therapy	O
for	O
chronic	O
hepatitis	O
C	O
:	O
Lessons	O
from	O
the	O
HALT	O
-	O
C	O
trial	O
.	O

METHODS	O
:	O
All	O
patients	O
had	O
failed	O
prior	O
treatment	O
with	O
IFN	O
or	O
peginterferon	O
+	O
/	O
-	O
RBV	O
and	O
had	O
Ishak	O
fibrosis	O
scores	O
>	O
or	O
=	O
3	O
.	O

Four	B-P
groups	I-P
of	I-P
patients	I-P
with	I-P
increasingly	I-P
severe	I-P
liver	I-P
disease	I-P
were	O
compared	O
:	O
(	O
A	O
)	O
bridging	B-I
fibrosis	I-I
(	I-I
Ishak	I-I
3	I-I
and	I-I
4	I-I
)	I-I
with	I-I
platelet	I-I
counts	I-I
>	I-I
125	I-I
,	I-I
000	I-I
/	I-I
mm3	I-I
(	O
n	O
=	O
559	O
)	O
;	O
(	O
B	O
)	O
bridging	B-I
fibrosis	I-I
with	I-I
platelet	I-I
counts	I-I
<	I-I
or	I-I
=125	I-I
,	I-I
000	I-I
/	I-I
mm3	I-I
(	O
n	O
=	O
96	O
)	O
;	O
(	O
C	O
)	O
cirrhosis	B-I
(	I-I
Ishak	I-I
5	I-I
and	I-I
6	I-I
)	I-I
with	I-I
platelet	I-I
counts	I-I
>	I-I
125	I-I
,	I-I
000	I-I
/	I-I
mm3	I-I
(	O
n	O
=	O
198	O
)	O
;	O
and	O
(	O
D	O
)	O
cirrhosis	B-I
with	I-I
platelet	I-I
counts	I-I
<	I-I
or	I-I
=125	I-I
,	I-I
000	I-I
/	I-I
mm3	I-I
(	O
n	O
=	O
193	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Cognitive	B-I
-	I-I
behavioural	I-I
stress	I-I
management	I-I
with	O
HIV	B-P
-	I-P
positive	I-P
homosexual	I-P
men	I-P
:	O
mechanisms	O
of	O
sustained	O
reductions	O
in	O
depressive	O
symptoms	O
.	O

METHODS	O
:	O
Men	O
were	O
randomized	O
to	O
either	O
a	B-I
10	I-I
-	I-I
week	I-I
,	I-I
group	I-I
-	I-I
based	I-I
CBSM	I-I
intervention	O
(	O
n	O
=	O
83	O
)	O
or	O
a	B-I
psychoeducational	I-I
seminar	I-I
group	O
(	O
n	O
=	O
46	O
)	O
.	O

All	O
participants	O
completed	O
a	B-O
battery	I-O
of	I-O
psychosocial	I-O
questionnaires	I-O
administered	O
by	O
a	O
research	O
assistant	O
at	O
baseline	O
,	O
immediately	O
following	O
the	B-I
10	I-I
-	I-I
week	I-I
CBSM	I-I
intervention	O
period	O
,	O
and	O
at	O
a	O
6	O
-	O
month	O
follow	O
-	O
up	O
.	O

-DOCSTART-	O

Title	O
:	O
Dietary	O
status	O
and	O
impact	O
of	O
risperidone	B-I
on	O
nutritional	O
balance	O
in	O
children	B-P
with	I-P
autism	I-P
:	O
a	O
pilot	O
study	O
.	O

METHODS	O
:	O
Using	O
a	B-O
quantitative	I-O
Food	I-O
Frequency	I-O
Questionnaire	I-O
(	I-O
FFQ	I-O
)	I-O
,	O
we	O
prospectively	O
examined	O
the	B-O
nutritional	I-O
intake	I-O
of	O
20	B-P
children	I-P
with	I-P
autism	I-P
participating	O
in	O
a	O
randomised	O
placebo	O
-	O
controlled	O
trial	O
of	O
risperidone	B-I
for	O
disruptive	O
behaviours	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
additional	O
value	O
of	O
a	B-I
night	I-I
splint	I-I
to	I-I
eccentric	I-I
exercises	I-I
in	O
chronic	O
midportion	O
Achilles	O
tendinopathy	O
:	O
a	O
randomised	O
controlled	O
trial	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
single	O
-	O
blind	O
,	O
prospective	O
,	O
single	O
centre	O
,	O
randomised	O
controlled	O
trial	O
set	O
in	O
the	O
Sports	O
Medical	O
Department	O
,	O
The	O
Hague	O
Medical	O
Centre	O
,	O
The	O
Netherlands	O
.	O

Inclusion	O
criteria	O
were	O
:	O
age	O
18	O
-	O
70	O
years	O
,	O
active	O
participation	O
in	O
sports	O
,	O
and	O
tendon	O
pain	O
localised	O
at	O
2	O
-	O
7	O
cm	O
from	O
distal	O
insertion	O
.	O

Exclusion	O
criteria	O
were	O
:	O
insertional	O
disorders	O
,	O
partial	O
or	O
complete	O
ruptures	O
,	O
or	O
systemic	O
illness	O
.	O

70	B-P
tendons	I-P
were	O
included	O
and	O
randomised	O
into	O
one	O
of	O
two	O
treatment	O
groups	O
:	O
eccentric	B-I
exercises	I-I
with	I-I
a	I-I
night	I-I
splint	I-I
(	O
night	B-I
splint	I-I
group	O
,	O
n	O
=	O
36	O
)	O
or	O
eccentric	B-I
exercises	I-I
only	I-I
(	O
eccentric	B-I
group	O
,	O
n	O
=	O
34	O
)	O
.	O

Both	O
groups	O
completed	O
a	B-I
12	I-I
-	I-I
week	I-I
heavy	I-I
-	I-I
load	I-I
eccentric	I-I
training	I-I
programme	I-I
.	O

One	O
group	O
received	O
a	O
night	O
splint	O
in	O
addition	O
to	O
eccentric	O
exercises	O
.	O

At	O
baseline	O
and	O
follow	O
-	O
up	O
at	O
12	O
weeks	O
,	O
patient	B-O
satisfaction	I-O
,	O
Victorian	B-O
Institute	I-O
of	I-O
Sport	I-O
Assessment	I-O
-	I-O
Achilles	I-O
questionnaire	I-O
(	I-O
VISA	I-O
-	I-O
A	I-O
)	I-O
score	I-O
and	O
reported	B-O
compliance	I-O
were	O
recorded	O
by	O
a	O
single	O
-	O
blind	O
trained	O
researcher	O
who	O
was	O
blinded	O
to	O
the	O
treatment	O
.	O

-DOCSTART-	O

Title	O
:	O
Developmental	B-I
disabilities	I-I
modification	I-I
of	I-I
the	I-I
Children	I-I
'	I-I
s	I-I
Global	I-I
Assessment	I-I
Scale	I-I
.	O

METHODS	O
:	O
Developmental	B-I
disabilities	I-I
-	I-I
relevant	I-I
descriptors	I-I
were	O
developed	O
for	O
the	B-O
DD	I-O
-	I-O
CGAS	I-O
,	O
and	O
administration	O
procedures	O
were	O
established	O
to	O
enhance	O
rater	O
consistency	O
.	O

Ratings	B-O
of	I-O
clinical	I-O
case	I-O
vignettes	I-O
were	O
used	O
to	O
assess	O
inter	B-O
-	I-O
rater	I-O
reliability	I-O
and	O
temporal	B-O
stability	I-O
.	O

Validity	B-O
was	O
assessed	O
by	O
correlating	O
the	B-O
DD	I-O
-	I-O
CGAS	I-O
with	O
measures	B-O
of	I-O
functioning	I-O
and	O
symptoms	B-O
in	O
83	B-P
youngsters	I-P
with	I-P
PDD	I-P
.	O

Sensitivity	O
to	O
change	O
was	O
assessed	O
by	O
comparing	O
change	O
from	O
baseline	O
to	O
post	O
-	O
treatment	O
with	O
change	O
on	O
the	B-O
Aberrant	I-O
Behavior	I-O
Checklist	I-O
-	I-O
Irritability	I-O
and	O
Clinical	B-O
Global	I-O
Impressions	I-O
-	I-O
Improvement	I-O
subscale	I-O
scores	I-O
in	O
a	O
subset	O
of	O
14	O
children	O
.	O

-DOCSTART-	O

Title	O
:	O
Desmopressin	B-I
in	O
the	O
treatment	O
of	O
nocturia	O
:	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
.	O

METHODS	O
:	O
Adults	B-P
aged	I-P
>	I-P
or	I-P
=18	I-P
yr	I-P
with	I-P
nocturia	I-P
(	I-P
>	I-P
or	I-P
=2	I-P
voids	I-P
/	I-P
night	I-P
)	I-P
received	O
desmopressin	B-I
tablets	I-I
(	O
0	O
.	O
1	O
,	O
0	O
.	O
2	O
,	O
or	O
0	O
.	O
4	O
mg	O
)	O
during	O
a	O
3	O
-	O
wk	O
dose	O
-	O
titration	O
period	O
.	O

Patients	O
should	O
show	O
sufficient	O
response	O
during	O
the	O
dose	O
-	O
titration	O
period	O
(	O
>	O
or	O
=20	O
%	O
reduction	O
in	O
nocturnal	O
diuresis	O
)	O
and	O
a	O
return	O
of	O
nocturnal	O
diuresis	O
to	O
>	O
or	O
=80	O
%	O
of	O
baseline	O
levels	O
during	O
washout	O
.	O

Eligible	O
patients	O
then	O
entered	O
a	O
3	O
-	O
wk	O
double	O
-	O
blind	O
treatment	O
period	O
and	O
received	O
either	O
desmopressin	B-I
or	O
placebo	B-C
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Effect	O
of	O
alpha	B-I
dihydroergocryptine	I-I
in	O
patients	B-P
with	I-P
fibrocystic	I-P
breast	I-P
disease	I-P
]	O
.	O

METHODS	O
:	O
Patients	B-P
with	I-P
diagnosis	I-P
of	I-P
fibrocystic	I-P
breast	I-P
disease	I-P
were	O
included	O
in	O
a	O
prospective	O
longitudinal	O
blind	O
double	O
,	O
controlled	O
with	O
placebo	O
study	O
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
treatment	O
groups	O
:	O
of	O
treatment	O
group	O
A	O
:	O
Alpha	B-I
dihidroergocriptine	I-I
tablets	I-I
of	O
10	O
mg	O
,	O
group	O
B	O
:	O
Placebo	B-C
,	O
during	O
6	O
months	O
.	O

After	O
to	O
basal	O
evaluation	O
,	O
the	O
patients	O
were	O
revised	O
in	O
a	O
monthly	O
way	O
evaluating	O
the	O
following	O
symptoms	B-O
and	I-O
signs	I-O
:	O
mastalgia	B-O
,	O
mammary	B-O
tension	I-O
,	O
presence	B-O
of	I-O
nodules	I-O
,	O
nipple	B-O
secretion	I-O
,	O
and	O
the	B-O
presence	I-O
of	I-O
adverse	I-O
events	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Immediately	O
restored	O
,	O
single	B-I
-	I-I
tapered	I-I
implants	I-I
in	O
the	O
anterior	O
maxilla	O
:	O
prosthodontic	O
and	O
aesthetic	O
outcomes	O
after	O
1	O
year	O
.	O

METHODS	O
:	O
Participants	B-P
(	I-P
mean	I-P
age	I-P
:	I-P
43	I-P
.	I-P
25	I-P
years	I-P
;	I-P
range	I-P
:	I-P
23	I-P
-	I-P
71	I-P
years	I-P
)	I-P
satisfying	I-P
specified	I-P
inclusion	I-P
criteria	I-P
were	O
randomly	O
allocated	O
to	O
conventional	B-C
two	I-C
-	I-C
stage	I-C
restoration	I-C
(	O
control	O
group	O
;	O
n=14	O
)	O
and	O
immediate	B-I
restoration	I-I
groups	O
(	O
test	O
group	O
;	O
n	O
=14	O
)	O
in	O
a	O
randomized	O
controlled	O
clinical	O
trial	O
.	O

Tapered	B-I
,	I-I
roughened	I-I
-	I-I
surface	I-I
Southern	I-I
implants	I-I
were	O
placed	O
using	O
a	O
standardized	O
technique	O
,	O
and	O
implant	B-O
level	I-O
bone	I-O
impressions	I-O
were	O
made	O
.	O

Provisional	O
screw	O
-	O
retained	O
crowns	O
,	O
out	O
of	O
occlusion	O
,	O
were	O
placed	O
at	O
second	O
-	O
stage	O
surgery	O
after	O
26	O
weeks	O
for	O
the	B-C
conventional	I-C
restoration	I-C
group	O
,	O
and	O
within	O
4	O
hours	O
of	O
implant	O
placement	O
for	O
the	B-I
immediate	I-I
restoration	I-I
group	O
.	O

Both	O
groups	O
had	O
definitive	O
screw	O
-	O
retained	O
metal	O
-	O
ceramic	O
crowns	O
placed	O
in	O
occlusion	O
8	O
weeks	O
later	O
.	O

Peri	B-O
-	I-O
implant	I-O
mucosal	I-O
response	I-O
and	O
papilla	B-O
index	I-O
were	O
recorded	O
4	O
weeks	O
after	O
definitive	O
crown	O
placement	O
to	O
allow	O
for	O
mucosal	O
maturation	O
and	O
at	O
1	O
year	O
.	O

Prosthodontic	B-O
and	O
aesthetic	B-O
outcomes	I-O
were	O
assessed	O
using	O
established	O
criteria	O
.	O

-DOCSTART-	O

Title	O
:	O
Low	O
efficacy	O
of	O
mebendazole	B-I
against	O
hookworm	O
in	O
Vietnam	B-P
:	O
two	O
randomized	O
controlled	O
trials	O
.	O

METHODS	O
:	O
We	O
tested	O
the	O
efficacy	O
of	O
single	B-I
dose	I-I
mebendazole	I-I
500	O
mg	O
in	O
the	O
therapy	O
of	O
hookworm	O
infection	O
in	O
a	O
randomized	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
trial	O
among	O
271	B-P
Vietnamese	I-P
schoolchildren	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Clinical	O
evaluation	O
of	O
imidapril	B-I
in	O
congestive	O
heart	O
failure	O
in	O
dogs	B-P
:	O
results	O
of	O
the	O
EFFIC	O
study	O
.	O

METHODS	O
:	O
This	O
good	O
,	O
clinical	O
practice	O
compliant	O
,	O
multicentre	O
study	O
(	O
EFFIC	O
study	O
)	O
enrolled	O
142	B-P
client	I-P
-	I-P
owned	I-P
dogs	I-P
and	O
was	O
conducted	O
in	O
20	O
locations	O
in	O
France	O
,	O
Belgium	O
and	O
Germany	O
.	O

Dogs	O
of	O
various	O
breed	O
,	O
age	O
and	O
weight	O
were	O
included	O
in	O
the	O
study	O
.	O

These	O
dogs	O
were	O
randomised	O
into	O
two	O
groups	O
that	O
were	O
treated	O
for	O
84	O
days	O
with	O
either	O
the	O
test	O
product	O
,	O
imidapril	B-I
,	O
or	O
the	O
positive	O
control	O
,	O
benazepril	B-C
,	O
and	O
followed	O
up	O
in	O
parallel	O
over	O
this	O
period	O
.	O

Both	O
treatments	O
were	O
administered	O
at	O
a	O
dose	O
of	O
0	O
.	O
25	O
mg	O
/	O
kg	O
once	O
a	O
day	O
with	O
the	O
possibility	O
of	O
doubling	O
this	O
dose	O
to	O
0	O
.	O
5	O
mg	O
/	O
kg	O
if	O
considered	O
necessary	O
from	O
a	O
clinical	O
point	O
of	O
view	O
.	O

In	O
addition	O
,	O
concomitant	O
treatment	O
was	O
given	O
to	O
dogs	O
presenting	O
with	O
pulmonary	O
oedema	O
and	O
/	O
or	O
ascites	O
,	O
supraventricular	O
tachyarrhythmia	O
and	O
/	O
or	O
dilated	O
cardiomyopathy	O
.	O

The	O
evolution	O
of	O
the	B-O
New	I-O
York	I-O
Heart	I-O
Association	I-O
stage	I-O
and	O
the	B-O
"	I-O
functional	I-O
signs	I-O
"	I-O
score	I-O
were	O
evaluated	O
as	O
primary	O
efficacy	O
criteria	O
.	O

-DOCSTART-	O

Title	O
:	O
Fine	B-I
needle	I-I
aspiration	I-I
coupled	O
with	O
real	B-I
-	I-I
time	I-I
PCR	I-I
:	O
a	O
painless	O
methodology	O
to	O
study	O
adaptive	O
functional	O
changes	O
in	O
skeletal	O
muscle	O
.	O

-DOCSTART-	O

Title	O
:	O
Injury	O
and	O
illness	O
costs	O
in	O
the	B-I
Certified	I-I
Safe	I-I
Farm	I-I
study	O
.	O

METHODS	O
:	O
Farms	B-P
(	I-P
316	I-P
)	I-P
located	I-P
in	I-P
a	I-P
9	I-P
-	I-P
county	I-P
area	I-P
of	I-P
northwestern	I-P
Iowa	I-P
were	O
recruited	O
and	O
randomized	O
into	O
intervention	O
and	O
control	O
cohorts	O
.	O

Intervention	O
farms	O
received	O
occupational	B-I
health	I-I
screenings	I-I
,	O
health	B-I
and	I-I
wellness	I-I
screening	I-I
,	O
education	B-I
,	O
on	B-I
-	I-I
farm	I-I
safety	I-I
reviews	I-I
,	O
and	O
performance	B-I
incentives	I-I
.	O

For	O
both	O
cohorts	O
,	O
quarterly	O
calls	O
over	O
3	O
years	O
were	O
used	O
to	O
collect	B-O
self	I-O
-	I-O
reported	I-O
occupational	I-O
injury	I-O
and	O
illness	B-O
information	I-O
,	O
including	O
costs	B-O
to	I-O
the	I-O
farmers	I-O
and	O
their	B-O
insurers	I-O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Effects	O
of	O
hetero	B-I
-	I-I
thermal	I-I
water	I-I
administration	O
on	O
leg	O
vein	O
hemodynamics	O
,	O
skin	O
microcirculation	O
and	O
O2	O
tension	O
in	O
chronic	O
venous	O
insufficiency	O
]	O
.	O

-DOCSTART-	O

Title	O
:	O
An	O
exploratory	O
,	O
pragmatic	O
,	O
cluster	O
randomised	O
trial	O
of	O
practice	B-I
nurse	I-I
training	I-I
in	O
the	O
use	O
of	O
asthma	O
action	O
plans	O
.	O

METHODS	O
:	O
A	O
pragmatic	O
,	O
cluster	O
randomised	O
trial	O
with	O
an	O
intervention	O
(	O
an	B-I
interactive	I-I
seminar	I-I
)	O
delivered	O
at	O
practice	O
level	O
(	O
n=13	O
practices	O
;	O
6=intervention	O
,	O
7=control	O
)	O
.	O

The	O
impact	O
of	O
the	O
intervention	O
was	O
assessed	O
against	O
patient	O
outcomes	O
:	O
routinely	B-O
available	I-O
asthma	I-O
outcome	I-O
measures	I-O
(	O
beta2	B-O
-	I-O
agonist	I-O
prescription	I-O
rate	I-O
and	O
number	B-O
of	I-O
oral	I-O
steroid	I-O
courses	I-O
)	O
for	O
asthma	O
patients	O
identified	O
as	O
being	O
poorly	O
-	O
controlled	O
from	O
practice	O
records	O
;	O
and	O
questionnaire	B-O
data	I-O
-	O
Mini	B-O
Asthma	I-O
Quality	I-O
of	I-O
Life	I-O
Questionnaire	I-O
(	I-O
AQLQ	I-O
)	I-O
and	O
the	B-O
Asthma	I-O
Control	I-O
Questionnaire	I-O
(	I-O
ACQ	I-O
)	I-O
-	O
from	O
a	O
subset	O
of	O
consenting	O
patients	O
.	O

Data	O
was	O
collected	O
at	O
baseline	O
and	O
at	O
6	O
-	O
month	O
follow	O
-	O
up	O
.	O

ANALYSISs	O
:	O
Routine	O
data	O
was	O
analysed	O
for	O
629	O
patients	O
.	O

236	O
(	O
37	O
%	O
)	O
of	O
these	O
patients	O
consented	O
to	O
provide	O
questionnaire	O
data	O
at	O
baseline	O
,	O
with	O
75	O
%	O
returning	O
questionnaires	O
at	O
follow	O
-	O
up	O
.	O

After	O
adjustment	O
for	O
baseline	O
and	O
practice	O
,	O
there	O
was	O
a	O
significant	O
difference	O
at	O
followup	O
between	O
intervention	O
and	O
control	O
practices	O
on	O
the	O
Mini	O
AQLQ	O
only	O
(	O
p=0	O
.	O
03	O
)	O
.	O

Estimates	O
for	O
subsequent	O
sample	O
sizes	O
to	O
inform	O
future	O
trials	O
of	O
asthma	O
training	O
were	O
identified	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
vacuum	B-I
-	I-I
compression	I-I
therapy	I-I
on	O
healing	O
of	O
diabetic	B-P
foot	I-P
ulcers	I-P
:	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Eighteen	B-P
diabetic	I-P
patients	I-P
with	I-P
foot	I-P
ulcers	I-P
were	O
recruited	O
through	O
simple	O
nonprobability	O
sampling	O
.	O

Subjects	O
were	O
randomly	O
assigned	O
to	O
either	O
an	O
experimental	O
or	O
a	O
control	O
group	O
.	O

Before	O
and	O
after	O
intervention	O
,	O
the	B-O
foot	I-O
ulcer	I-O
surface	I-O
area	I-O
was	O
estimated	O
stereologically	O
,	O
based	O
on	B-O
Cavalieri	I-O
'	I-O
s	I-O
principle	I-O
.	O

The	O
experimental	O
group	O
was	O
treated	O
with	O
VCT	B-I
in	O
addition	O
to	O
conventional	B-C
therapy	I-C
for	O
10	O
sessions	O
.	O

The	O
control	O
group	O
received	O
only	B-C
conventional	I-C
therapy	I-C
,	O
including	O
debridement	B-C
,	O
blood	B-C
glucose	I-C
control	I-C
agents	I-C
,	O
systemic	B-C
antibiotics	I-C
,	O
wound	B-C
cleaning	I-C
with	I-C
normal	I-C
saline	I-C
,	O
offloading	B-C
(	I-C
pressure	I-C
relief	I-C
)	I-C
,	O
and	O
daily	B-C
wound	I-C
dressings	I-C
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
of	O
intravenous	B-I
acetaminophen	I-I
and	O
lidocaine	B-I
on	O
propofol	O
injection	O
pain	O
.	O

METHODS	O
:	O
One	B-P
hundred	I-P
and	I-P
fifty	I-P
ASA	I-P
I	I-P
-	I-P
II	I-P
patients	I-P
undergoing	I-P
general	I-P
anaesthesia	I-P
were	O
randomly	O
allocated	O
into	O
three	O
groups	O
.	O

A	O
20	O
-	O
gauge	O
catheter	O
was	O
inserted	O
into	O
a	O
superficial	O
radial	O
vein	O
of	O
the	O
left	O
hand	O
,	O
and	O
after	O
the	O
occlusion	O
of	O
venous	O
drainage	O
,	O
Groups	O
I	O
,	O
II	O
,	O
and	O
III	O
were	O
pretreated	O
with	O
40	B-I
mg	I-I
of	I-I
lidocaine	I-I
in	I-I
saline	I-I
,	O
50	B-I
mg	I-I
of	I-I
i	I-I
.	I-I
v	I-I
.	I-I
acetaminophen	I-I
,	O
and	O
5	B-C
ml	I-C
of	I-C
saline	I-C
,	O
respectively	O
.	O

The	O
occlusion	O
was	O
released	O
after	O
2	O
min	O
and	O
one	O
-	O
fourth	O
of	O
the	O
total	O
propofol	O
dose	O
was	O
injected	O
into	O
the	O
vein	O
over	O
a	O
period	O
of	O
5	O
s	O
.	O

During	O
the	O
injection	O
of	O
both	O
pretreatment	O
solution	O
and	O
propofol	O
,	O
patients	B-O
'	I-O
pain	I-O
was	O
assessed	O
and	O
recorded	O
as	O
0	O
-	O
3	O
,	O
corresponding	O
to	O
no	B-O
,	O
mild	B-O
,	O
moderate	B-O
or	O
severe	B-O
pain	I-O
,	O
respectively	O
.	O

Chi2	O
and	O
Kruskal	O
-	O
Wallis	O
tests	O
were	O
used	O
for	O
the	O
statistical	O
analysis	O
.	O

For	O
all	O
analyses	O
,	O
differences	O
were	O
considered	O
to	O
be	O
significant	O
at	O
P	O
<	O
0	O
.	O
05	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
prospective	O
randomized	O
treatment	O
study	O
comparing	O
three	O
treatment	O
options	O
for	O
chalazia	O
:	O
triamcinolone	B-I
acetonide	I-I
injections	I-I
,	O
incision	B-I
and	O
curettage	B-I
and	O
treatment	O
with	O
hot	B-I
compresses	I-I
.	O

METHODS	O
:	O
This	O
was	O
a	O
single	O
centre	O
randomized	O
treatment	O
study	O
.	O

Patients	B-P
with	I-P
a	I-P
chalazion	I-P
underwent	O
either	O
of	O
the	O
three	O
treatment	O
options	O
.	O

Chalazion	B-O
resolution	I-O
,	O
pain	B-O
,	O
satisfaction	B-O
and	O
inconvenience	B-O
experienced	I-O
because	I-O
of	I-O
treatments	I-O
were	O
the	O
outcomes	O
assessed	O
via	O
a	O
telephone	O
interview	O
at	O
3	O
weeks	O
.	O

-DOCSTART-	O

Title	O
:	O
Minimally	B-I
invasive	I-I
treatment	I-I
combined	O
with	O
cytokine	B-I
-	I-I
induced	I-I
killer	I-I
cells	I-I
therapy	I-I
lower	O
the	O
short	O
-	O
term	O
recurrence	O
rates	O
of	O
hepatocellular	O
carcinomas	O
.	O

METHODS	O
:	O
Therefore	O
,	O
85	B-P
HCC	I-P
patients	I-P
after	I-P
transcatheter	I-P
arterial	I-P
chemoembolization	I-P
and	I-P
radiofrequency	I-P
ablation	I-P
therapy	I-P
were	O
randomized	O
to	O
immunotherapy	B-I
group	O
and	O
no	B-I
adjuvant	I-I
therapy	I-I
group	O
.	O

Autologous	O
cytokine	O
-	O
induced	O
killer	O
(	O
CIK	O
)	O
cells	O
were	O
transfused	O
via	O
hepatic	O
artery	O
to	O
the	O
patients	O
.	O

The	B-O
alteration	I-O
of	I-O
levels	I-O
of	I-O
lymphocyte	I-O
subsets	I-O
in	O
peripheral	B-O
blood	I-O
of	O
patients	O
was	O
examined	O
by	O
flow	B-O
cytometry	I-O
.	O

All	O
patients	O
were	O
screened	O
by	O
computed	B-O
tomography	I-O
every	O
2	O
months	O
to	O
observe	O
the	B-O
tumor	I-O
recurrent	I-O
conditions	I-O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
effect	O
of	O
coenzyme	B-I
Q10	I-I
on	O
microcirculatory	O
endothelial	O
function	O
of	O
subjects	B-P
with	I-P
type	I-P
2	I-P
diabetes	I-P
mellitus	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Reduced	O
albuminuria	O
with	O
sarpogrelate	B-I
is	O
accompanied	O
by	O
a	O
decrease	O
in	O
monocyte	O
chemoattractant	O
protein	O
-	O
1	O
levels	O
in	O
type	O
2	O
diabetes	O
.	O

METHODS	O
:	O
Forty	B-P
patients	I-P
who	I-P
had	I-P
diabetes	I-P
with	I-P
nephropathy	I-P
and	I-P
arteriosclerosis	I-P
obliterans	I-P
and	I-P
had	I-P
already	I-P
been	I-P
treated	I-P
with	I-P
angiotensin	I-P
II	I-P
receptor	I-P
blocker	I-P
(	I-P
n	I-P
=	I-P
40	I-P
)	I-P
were	O
randomly	O
assigned	O
to	O
sarpogrelate	B-I
(	O
300	O
mg	O
/	O
d	O
;	O
n	O
=	O
20	O
)	O
or	O
aspirin	B-I
group	O
(	O
100	O
mg	O
/	O
d	O
;	O
n	O
=	O
20	O
)	O
.	O

Plasma	B-O
monocyte	I-O
chemoattractant	I-O
protein	I-O
-	I-O
1	I-O
and	O
urinary	B-O
albumin	I-O
-	I-O
to	I-O
-	I-O
creatinine	I-O
ratio	I-O
and	O
monocyte	B-O
chemoattractant	I-O
protein	I-O
-	I-O
1	I-O
were	O
measured	O
at	O
baseline	O
and	O
16	O
wk	O
after	O
administration	O
.	O

-DOCSTART-	O

Title	O
:	O
The	B-I
dipeptidyl	I-I
peptidase	I-I
-	I-I
4	I-I
inhibitor	I-I
PHX1149	I-I
improves	O
blood	O
glucose	O
control	O
in	O
patients	B-P
with	I-P
type	I-P
2	I-P
diabetes	I-P
mellitus	I-P
.	O

METHODS	O
:	O
This	O
is	O
a	O
multicentre	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
4	O
-	O
week	O
study	O
in	O
patients	B-P
with	I-P
type	I-P
2	I-P
diabetes	I-P
with	I-P
suboptimal	I-P
metabolic	I-P
control	I-P
.	O

Patients	B-P
with	I-P
a	I-P
baseline	I-P
haemoglobin	I-P
A	I-P
(	I-P
1c	I-P
)	I-P
(	I-P
HbA	I-P
(	I-P
1c	I-P
)	I-P
)	I-P
of	I-P
7	I-P
.	I-P
3	I-P
to	I-P
11	I-P
.	I-P
0	I-P
%	I-P
were	O
randomized	O
1	O
:	O
1	O
:	O
1	O
:	O
1	O
to	O
receive	O
once	O
-	O
daily	O
oral	O
therapy	O
with	O
either	O
PHX1149	B-I
(	O
100	O
,	O
200	O
or	O
400	O
mg	O
)	O
or	O
placebo	B-C
;	O
patients	O
were	O
on	O
a	O
constant	O
background	O
therapy	O
of	O
either	O
metformin	O
alone	O
or	O
metformin	O
plus	O
a	O
glitazone	O
.	O

-DOCSTART-	O

Title	O
:	O
Testosterone	B-I
and	O
gonadotropins	B-I
but	O
not	O
estrogen	B-I
associated	O
with	O
spatial	O
ability	O
in	O
women	B-P
suffering	I-P
from	I-P
schizophrenia	I-P
:	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
.	O

METHODS	O
:	O
For	O
this	O
purpose	O
,	O
a	O
placebo	O
-	O
controlled	O
,	O
double	O
-	O
blind	O
,	O
three	O
-	O
time	O
cross	O
-	O
over	O
study	O
using	O
17beta	B-I
-	I-I
estradiol	I-I
combined	O
with	O
norethisterone	B-I
acetate	I-I
for	O
replacement	O
therapy	O
and	O
as	O
an	O
adjunct	O
to	O
a	O
naturalistic	O
maintenance	O
antipsychotic	O
treatment	O
was	O
carried	O
out	O
over	O
a	O
period	O
of	O
8	O
months	O
.	O

Nineteen	B-P
women	I-P
(	I-P
mean	I-P
age=38	I-P
.	I-P
0	I-P
years	I-P
,	I-P
SD=9	I-P
.	I-P
9	I-P
years	I-P
)	I-P
with	I-P
schizophrenia	I-P
hospitalized	I-P
for	I-P
the	I-P
first	I-P
time	I-P
or	I-P
repeatedly	I-P
were	I-P
included	I-P
in	I-P
the	I-P
study	I-P
.	O

Sex	B-O
hormones	I-O
-	O
17beta	B-O
-	I-O
estradiol	I-O
,	I-O
luteinizing	B-O
hormone	I-O
(	I-O
LH	I-O
)	I-O
,	O
follicle	B-O
-	I-O
stimulating	I-O
hormone	I-O
(	I-O
FSH	I-O
)	I-O
,	O
prolactin	B-O
,	O
testosterone	B-O
,	O
and	O
dehydroepiandrosterone	B-O
sulfate	I-O
-	O
were	O
measured	O
and	O
the	O
patients	O
completed	O
a	B-O
neuropsychological	I-O
test	I-O
in	O
the	O
last	O
two	O
active	O
drug	O
and	O
/	O
or	O
placebo	B-C
phases	O
.	O

Three	O
different	O
spatial	O
ability	O
tasks	O
-	O
spatial	B-O
orientation	I-O
,	O
spatial	B-O
visualization	I-O
,	O
and	O
flexibility	B-O
of	I-O
closure	I-O
-	O
were	O
measured	O
by	O
a	B-O
paper	I-O
-	I-O
and	I-O
-	I-O
pencil	I-O
test	I-O
.	O

-DOCSTART-	O

Title	O
:	O
New	B-I
introducer	I-I
PEG	I-I
gastropexy	I-I
does	O
not	O
require	O
prophylactic	B-I
antibiotics	I-I
:	O
multicenter	O
prospective	O
randomized	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
study	O
.	O

METHODS	O
:	O
Prospective	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
.	O

Multicenter	O
;	O
a	O
university	O
tertiary	O
-	O
care	O
hospital	O
and	O
a	O
private	O
practice	O
endoscopy	O
clinic	O
.	O

A	O
total	O
of	O
633	O
patients	O
undergoing	O
PEG	O
were	O
assessed	O
for	O
inclusion	O
.	O

Ninety	B-P
-	I-P
seven	I-P
patients	I-P
who	I-P
had	I-P
malignant	I-P
stenotic	I-P
oropharyngeal	I-P
stricture	I-P
were	O
randomized	O
:	O
group	O
I	O
(	O
49	O
patients	O
)	O
received	O
prophylactic	B-I
ceftriaxone	I-I
,	O
and	O
group	O
II	O
(	O
48	O
patients	O
)	O
received	O
a	B-C
placebo	I-C
.	O

Both	O
groups	O
were	O
similar	O
in	O
patient	O
characteristics	O
.	O

Introducer	B-I
PEG	I-I
was	O
performed	O
by	O
using	O
the	B-I
Freka	I-I
Pexact	I-I
-	I-I
15	I-I
CH	I-I
/	I-I
FR	I-I
,	O
with	O
the	O
gastric	O
wall	O
nonsurgically	O
sutured	O
to	O
the	O
anterior	O
abdominal	O
wall	O
by	O
use	O
of	O
an	O
endoscope	O
.	O

The	B-O
peristomal	I-O
area	I-O
was	O
assessed	O
daily	O
for	O
7	O
days	O
by	O
using	O
2	B-O
different	I-O
types	I-O
of	I-O
infection	I-O
scores	I-O
.	O

-DOCSTART-	O

Title	O
:	O
A	B-I
simplified	I-I
4	I-I
-	I-I
site	I-I
economical	I-I
intradermal	I-I
post	I-I
-	I-I
exposure	I-I
rabies	I-I
vaccine	I-I
regimen	I-I
:	O
a	O
randomised	O
controlled	O
comparison	O
with	O
standard	O
methods	O
.	O

METHODS	O
:	O
Two	B-P
hundred	I-P
and	I-P
fifty	I-P
-	I-P
four	I-P
volunteers	I-P
were	O
randomly	O
allocated	O
to	O
a	O
single	O
blind	O
controlled	O
trial	O
.	O

Each	O
received	O
purified	O
vero	O
cell	O
rabies	O
vaccine	O
by	O
one	O
of	O
four	B-I
PEP	I-I
regimens	I-I
:	O
the	B-I
currently	I-I
accepted	I-I
2	I-I
-	I-I
site	I-I
ID	I-I
;	O
the	B-I
8	I-I
-	I-I
site	I-I
regimen	I-I
using	O
0	O
.	O
05	O
ml	O
per	O
ID	O
site	O
;	O
a	B-I
new	I-I
4	I-I
-	I-I
site	I-I
ID	I-I
regimen	I-I
(	O
on	O
day	O
0	O
,	O
approximately	O
0	O
.	O
1	O
ml	O
at	O
4	O
ID	O
sites	O
,	O
using	O
the	O
whole	O
0	O
.	O
5	O
ml	O
ampoule	O
of	O
vaccine	O
;	O
on	O
day	O
7	O
,	O
0	O
.	O
1	O
ml	O
ID	O
at	O
2	O
sites	O
and	O
at	O
one	O
site	O
on	O
days	O
28	O
and	O
90	O
)	O
;	O
or	O
the	B-C
standard	I-C
5	I-C
-	I-C
dose	I-C
intramuscular	I-C
regimen	I-C
.	O

All	O
ID	O
regimens	O
required	O
the	O
same	O
total	O
amount	O
of	O
vaccine	O
,	O
60	O
%	O
less	O
than	O
the	O
intramuscular	O
method	O
.	O

Neutralising	B-O
antibody	I-O
responses	I-O
were	O
measured	O
five	O
times	O
over	O
a	O
year	O
in	O
229	O
people	O
,	O
for	O
whom	O
complete	O
data	O
were	O
available	O
.	O

-DOCSTART-	O

Title	O
:	O
Predictive	O
validity	O
of	O
a	B-I
medication	I-I
adherence	I-I
measure	I-I
in	O
an	O
outpatient	O
setting	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
esomeprazole	B-I
triple	I-I
therapy	I-I
on	O
eradication	O
rates	O
of	O
Helicobacter	O
pylori	O
,	O
gastric	O
ulcer	O
healing	O
and	O
prevention	O
of	O
relapse	O
in	O
gastric	B-P
ulcer	I-P
patients	I-P
.	O

METHODS	O
:	O
In	O
this	O
double	O
-	O
blind	O
study	O
,	O
401	B-P
H	I-P
.	I-P
pylori	I-P
-	I-P
positive	I-P
patients	I-P
with	I-P
more	I-P
than	I-P
or	I-P
equal	I-P
to	I-P
two	I-P
GUs	I-P
were	O
randomized	O
to	O
:	O
esomeprazole	B-I
(	O
20	O
mg	O
)	O
twice	O
daily	O
(	O
bid	O
)	O
and	O
amoxicillin	B-I
(	O
1000	O
mg	O
)	O
bid	O
and	O
clarithromycin	B-I
(	O
500	O
mg	O
)	O
bid	O
(	O
EAC	B-I
)	O
for	O
1	O
week	O
,	O
followed	O
by	O
placebo	B-C
for	O
3	O
weeks	O
(	O
EAC	B-I
and	O
placebo	B-C
)	O
;	O
EAC	B-I
for	O
1	O
week	O
,	O
followed	O
by	O
esomeprazole	B-I
(	O
20	O
mg	O
)	O
once	O
daily	O
(	O
E20	B-I
)	O
for	O
3	O
weeks	O
(	O
EAC	B-I
and	O
E20	B-I
)	O
;	O
or	O
esomeprazole	B-I
(	O
20	O
mg	O
)	O
bid	O
and	O
placebo	B-C
antimicrobials	I-C
for	O
1	O
week	O
,	O
followed	O
by	O
E20	B-I
for	O
3	O
weeks	O
(	O
E20	B-I
bid	O
and	O
E20	B-I
)	O
.	O

Patients	O
with	O
unhealed	O
GUs	O
at	O
4	O
weeks	O
received	O
E20	B-I
for	O
an	O
additional	O
4	O
weeks	O
.	O

Healed	O
patients	O
were	O
followed	O
up	O
for	O
12	O
months	O
.	O

-DOCSTART-	O

Title	O
:	O
Penetration	O
and	O
accumulation	O
of	O
moxifloxacin	B-I
in	O
uterine	O
tissue	O
.	O

METHODS	O
:	O
In	O
a	O
prospective	O
,	O
multicenter	O
,	O
open	O
-	O
label	O
,	O
parallel	O
-	O
group	O
study	O
we	O
determined	O
the	O
concentration	B-O
of	I-O
moxifloxacin	I-O
in	I-O
plasma	I-O
and	O
uterine	B-O
tissue	I-O
after	O
a	B-I
single	I-I
,	I-I
400	I-I
-	I-I
mg	I-I
intravenous	I-I
dose	I-I
of	I-I
moxifloxacin	I-I
.	O

Study	O
participants	O
were	O
randomized	O
for	O
time	O
of	O
tissue	O
sampling	O
,	O
which	O
was	O
performed	O
1	O
,	O
2	O
,	O
4	O
,	O
7	O
,	O
or	O
24	O
hours	O
following	O
the	B-I
moxifloxacin	I-I
infusion	I-I
.	O

-DOCSTART-	O

Title	O
:	O
Heart	O
rate	O
variability	O
characteristics	O
in	O
sedentary	B-P
postmenopausal	I-P
women	I-P
following	O
six	B-I
months	I-I
of	I-I
exercise	I-I
training	I-I
:	O
the	O
DREW	O
study	O
.	O

-DOCSTART-	O

Title	O
:	O
Use	O
of	O
topical	B-I
selamectin	I-I
for	O
the	O
treatment	O
of	O
Syphacia	O
muris	O
infection	O
in	O
laboratory	B-P
rats	I-P
.	O

METHODS	O
:	O
Fourty	B-P
-	I-P
eight	I-P
S	I-P
.	I-P
muris	I-P
-	I-P
positive	I-P
rats	I-P
were	O
divided	O
into	O
six	O
treated	O
and	O
two	O
control	O
groups	O
.	O

Selamectin	B-I
(	O
6	O
mg	O
/	O
kg	O
)	O
was	O
applied	O
topically	O
to	O
the	O
skin	O
in	O
a	O
single	O
spot	O
at	O
the	O
base	O
of	O
the	O
neck	O
in	O
the	O
treatment	O
group	O
.	O

The	O
rats	O
of	O
treated	O
and	O
control	O
groups	O
were	O
necropsied	B-O
on	O
the	O
24th	O
day	O
after	O
the	O
treatment	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
comparison	O
between	O
the	O
effect	O
of	O
oxytocin	B-I
only	I-I
and	O
oxytocin	B-I
plus	O
propranolol	B-I
on	O
the	O
labor	O
(	O
a	O
double	O
blind	O
randomized	O
trial	O
)	O
.	O

METHODS	O
:	O
A	O
double	O
blind	O
randomized	O
controlled	O
trial	O
was	O
performed	O
on	O
150	B-P
nulliparas	I-P
with	I-P
a	I-P
gestational	I-P
age	I-P
of	I-P
39	I-P
-	I-P
41	I-P
weeks	I-P
of	I-P
pregnancy	I-P
and	I-P
a	I-P
Bishop	I-P
score	I-P
of	I-P
<	I-P
or	I-P
=5	I-P
.	O

In	O
the	O
first	O
group	O
(	O
oxytocin	O
group	O
=	O
75	O
)	O
,	O
oxytocin	B-I
alone	I-I
was	O
used	O
for	O
induction	O
of	O
labor	O
.	O

In	O
the	O
second	O
group	O
(	O
propranolol	B-I
group	O
=	O
75	O
cases	O
)	O
,	O
before	O
the	O
beginning	O
of	O
oxytocin	B-I
,	O
2	B-I
mg	I-I
propranolol	I-I
was	O
slowly	O
injected	O
intravenously	O
then	O
the	B-I
oxytocin	I-I
was	O
initiated	O
.	O

-DOCSTART-	O

Title	O
:	O
Central	O
neuronal	O
mechanisms	O
of	O
gastric	B-I
electrical	I-I
stimulation	I-I
in	O
diabetic	O
gastroparesis	O
.	O

METHODS	O
:	O
A	B-I
gastric	I-I
electrical	I-I
stimulator	I-I
was	O
implanted	O
in	O
seven	B-P
diabetic	I-P
patients	I-P
with	I-P
medically	I-P
refractory	I-P
gastroparesis	I-P
.	O

A	O
double	O
-	O
blinded	O
protocol	O
was	O
used	O
to	O
investigate	O
the	O
patients	O
at	O
baseline	O
and	O
one	O
month	O
after	O
recovery	O
with	O
the	B-I
stimulator	I-I
turned	O
on	O
and	O
off	O
(	O
1	O
-	O
month	O
periods	O
)	O
.	O

The	O
following	O
assessments	O
were	O
carried	O
out	O
:	O
mechanical	B-O
,	O
thermal	B-O
and	O
electrical	B-O
stimulations	I-O
with	I-O
sensory	I-O
recordings	I-O
in	I-O
the	I-O
esophagus	I-O
and	I-O
duodenum	I-O
,	O
and	O
standardized	B-O
,	O
self	B-O
-	I-O
administered	I-O
,	O
daily	B-O
symptom	I-O
questionnaires	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Combination	B-I
chemotherapy	I-I
and	O
ALVAC	B-I
-	I-I
CEA	I-I
/	I-I
B7	I-I
.	I-I
1	I-I
vaccine	I-I
in	O
patients	B-P
with	I-P
metastatic	I-P
colorectal	I-P
cancer	I-P
.	O

METHODS	O
:	O
Patients	B-P
with	I-P
metastatic	I-P
colorectal	I-P
cancer	I-P
were	O
treated	O
with	O
fluorouracil	B-I
,	O
leucovorin	B-I
,	O
and	O
irinotecan	B-I
and	O
were	O
also	O
given	O
ALVAC	B-I
-	I-I
CEA	I-I
/	I-I
B7	I-I
.	I-I
1	I-I
vaccine	I-I
with	I-I
or	O
without	B-I
tetanus	I-I
toxoid	I-I
adjuvant	I-I
.	O

Eligible	O
patients	O
were	O
randomized	O
to	O
ALVAC	B-I
followed	O
by	O
chemotherapy	B-I
and	O
booster	B-I
vaccination	I-I
(	O
group	O
1	O
)	O
,	O
ALVAC	B-I
and	O
tetanus	B-I
toxoid	I-I
followed	O
by	O
chemotherapy	B-I
(	O
group	O
2	O
)	O
,	O
or	O
chemotherapy	B-I
alone	I-I
followed	O
by	O
ALVAC	B-I
in	O
patients	O
without	O
disease	O
progression	O
(	O
group	O
3	O
)	O
.	O

Humoral	B-O
immune	I-O
responses	I-O
were	O
measured	O
by	O
standard	B-O
ELISA	I-O
assay	I-O
,	O
and	O
carcinoembryonic	B-O
antigen	I-O
(	I-O
CEA	I-O
)	I-O
-	I-O
specific	I-O
T	I-O
-	I-O
cell	I-O
responses	I-O
were	O
measured	O
by	O
IFN	B-O
-	I-O
gamma	I-O
enzyme	I-O
-	I-O
linked	I-O
immunospot	I-O
assay	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Beneficial	O
effects	O
of	O
a	B-I
diabetes	I-I
specific	I-I
formula	I-I
on	O
insulin	O
sensitivity	O
and	O
free	O
fatty	O
acid	O
in	O
patients	B-P
with	I-P
type	I-P
2	I-P
diabetes	I-P
mellitus	I-P
.	O

METHODS	O
:	O
In	B-P
total	I-P
of	I-P
71	I-P
type	I-P
2	I-P
diabetics	I-P
completed	O
the	O
study	O
.	O

Enteral	B-I
formulas	I-I
were	O
given	O
orally	O
as	O
the	O
sole	O
source	O
of	O
nutrition	O
to	O
the	O
subjects	O
for	O
6	O
days	O
.	O

Venous	O
blood	O
samples	O
(	O
0	O
.	O
5	O
,	O
1	O
,	O
2	O
,	O
3	O
hours	O
)	O
were	O
collected	O
at	O
day	O
-	O
7	O
after	O
a	O
75	O
g	O
oral	O
glucose	O
tolerance	O
test	O
(	O
OGTT	O
)	O
,	O
day	O
1	O
after	O
a	O
standard	O
test	O
meal	O
(	O
1673	O
.	O
6	O
kJ	O
)	O
and	O
after	O
6	O
days	O
of	O
either	O
the	B-I
test	I-I
diabetes	I-I
specific	I-I
formula	I-I
or	O
a	B-C
standard	I-C
formula	I-C
.	O

Plasma	B-O
glucose	I-O
,	O
serum	B-O
insulin	I-O
,	O
C	B-O
peptide	I-O
and	O
lipids	B-O
were	O
measured	O
.	O

-DOCSTART-	O

Title	O
:	O
Social	B-I
stories	I-I
:	O
mechanisms	O
of	O
effectiveness	O
in	O
increasing	O
game	O
play	O
skills	O
in	O
children	B-P
diagnosed	I-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
using	I-P
a	I-P
pretest	I-P
posttest	I-P
repeated	I-P
measures	I-P
randomized	I-P
control	I-P
group	I-P
design	I-P
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
45	I-P
children	I-P
diagnosed	I-P
with	I-P
Autism	I-P
Spectrum	I-P
Disorder	I-P
(	I-P
ASD	I-P
)	I-P
ages	I-P
7	I-P
-	I-P
14	I-P
were	O
randomly	O
assigned	O
to	O
standard	B-I
,	O
directive	B-I
,	O
or	O
control	B-C
story	I-C
conditions	I-C
.	O

-DOCSTART-	O

Title	O
:	O
Behavior	O
in	O
children	B-P
with	I-P
Down	I-P
syndrome	I-P
.	O

METHODS	O
:	O
Eight	B-P
children	I-P
with	I-P
Down	I-P
syndrome	I-P
who	I-P
displayed	I-P
autistic	I-P
features	I-P
were	O
compared	O
with	O
eight	O
Down	O
syndrome	O
children	O
without	O
autistic	O
features	O
.	O

These	O
children	O
were	O
randomly	O
selected	O
and	O
were	O
matched	O
for	O
age	O
and	O
level	O
of	O
retardation	O
.	O

Standardized	B-O
Psychological	I-O
tests	I-O
were	O
administered	O
to	O
tap	O
the	B-O
behavioral	I-O
differences	I-O
.	O

Mann	O
-	O
Whitney	O
U	O
test	O
was	O
used	O
for	O
significance	O
of	O
difference	O
between	O
both	O
the	O
groups	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
of	O
latanoprost	B-I
when	I-I
stored	I-I
at	I-I
room	I-I
temperature	I-I
.	O

METHODS	O
:	O
Latanoprost	B-I
0	I-I
.	I-I
005	I-I
%	I-I
(	I-I
Xalatan	I-I
)	I-I
was	O
stored	O
at	O
4	O
degrees	O
C	O
or	O
30	O
degrees	O
C	O
for	O
4	O
weeks	O
in	O
the	O
dark	O
.	O

The	O
subjects	O
enrolled	O
to	O
the	O
study	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
latanoprost	B-I
stored	I-I
at	I-I
4	I-I
degrees	I-I
C	I-I
or	O
that	B-I
stored	I-I
at	I-I
30	I-I
degrees	I-I
C	I-I
.	O

The	O
eye	O
drop	O
was	O
applied	O
to	O
the	O
right	O
eye	O
of	O
each	O
subject	O
for	O
3	O
days	O
.	O

The	O
left	O
eye	O
served	O
as	O
a	O
control	O
without	B-C
administration	I-C
.	O

Slit	B-O
-	I-O
lamp	I-O
biomicroscopy	I-O
and	O
circadian	B-O
intra	I-O
ocular	I-O
pressure	I-O
(	I-O
IOP	I-O
)	I-O
curve	I-O
was	O
performed	O
at	O
Day	O
3	O
,	O
every	O
3	O
hours	O
from	O
6	O
pm	O
.	O

This	O
procedure	O
was	O
repeated	O
7	O
days	O
after	O
changing	O
the	O
drug	O
from	O
4	O
degrees	O
C	O
to	O
30	O
degrees	O
C	O
or	O
vice	O
versa	O
,	O
and	O
application	O
to	O
the	O
left	O
eye	O
for	O
3	O
days	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
The	O
CARESS	O
-	O
in	O
-	O
AMI	O
trial	O
]	O
.	O

-DOCSTART-	O

Title	O
:	O
Monitoring	B-I
of	I-I
the	I-I
central	I-I
pulse	I-I
pressure	I-I
is	O
useful	O
for	O
detecting	O
cardiac	O
overload	O
during	O
antiadrenergic	O
treatment	O
:	O
the	O
Japan	O
Morning	O
Surge	O
1	O
study	O
.	O

METHODS	O
:	O
We	O
studied	O
434	B-P
treated	I-P
hypertensive	I-P
patients	I-P
whose	I-P
home	I-P
systolic	I-P
blood	I-P
pressure	I-P
was	I-P
135	I-P
mmHg	I-P
or	I-P
higher	I-P
.	I-P

They	O
were	O
followed	O
for	O
6	O
months	O
after	O
allocation	O
to	O
either	O
a	O
control	O
group	O
or	O
an	O
added	O
treatment	O
group	O
(	O
doxazosin	O
1	O
-	O
4	O
mg	O
and	O
atenolol	O
when	O
needed	O
)	O
.	O

We	O
measured	O
the	B-O
brachial	I-O
and	O
central	B-O
(	I-O
carotid	I-O
)	I-O
blood	I-O
pressure	I-O
simultaneously	O
using	O
a	B-O
validated	I-O
device	I-O
,	O
and	O
the	B-O
B	I-O
-	I-O
type	I-O
natriuretic	I-O
peptide	I-O
at	O
baseline	O
and	O
at	O
the	O
sixth	O
month	O
of	O
treatment	O
.	O

-DOCSTART-	O

Title	O
:	O
Safety	O
and	O
immunogenicity	O
of	O
a	B-I
cluster	I-I
specific	I-I
immunotherapy	I-I
in	O
children	B-P
with	I-P
bronchial	I-P
asthma	I-P
and	I-P
mite	I-P
allergy	I-P
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
34	I-P
children	I-P
(	I-P
6	I-P
-	I-P
18	I-P
years	I-P
)	I-P
with	I-P
allergic	I-P
asthma	I-P
were	O
assigned	O
to	O
cluster	B-I
(	O
n	O
=	O
22	O
)	O
or	O
classic	B-C
SIT	I-C
(	O
n	O
=	O
12	O
)	O
.	O

To	O
achieve	O
a	O
maintenance	O
dose	O
of	O
allergen	O
extract	O
,	O
cluster	B-I
patients	O
received	O
14	O
injections	O
of	O
house	O
dust	O
mite	O
allergen	O
within	O
6	O
weeks	O
,	O
whereas	O
the	O
classic	B-C
SIT	I-C
group	O
received	O
14	O
injections	O
within	O
14	O
weeks	O
.	O

Safety	B-O
was	O
monitored	O
by	O
recording	O
adverse	B-O
events	I-O
.	O

Immunogenicity	B-O
was	O
measured	O
by	O
specific	B-O
IgG	I-O
(	I-O
Mite	I-O
)	I-O
and	O
IgG4	B-O
(	I-O
Mite	I-O
)	O
,	O
by	O
antibody	B-O
-	I-O
blocking	I-O
properties	I-O
on	I-O
basophil	I-O
activation	I-O
,	O
and	O
by	O
the	B-O
T	I-O
cell	I-O
subset	I-O
transcription	I-O
factors	I-O
Foxp3	I-O
,	O
T	B-O
-	I-O
bet	I-O
,	O
and	O
GATA	B-O
-	I-O
3	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Two	O
-	O
year	O
prospective	O
clinical	O
comparison	O
of	O
immediate	B-I
replacement	I-I
vs	O
.	O
immediate	B-C
restoration	I-C
of	I-C
single	I-C
tooth	I-C
in	O
the	O
esthetic	O
zone	O
.	O

METHODS	O
:	O
Sixteen	B-P
patients	I-P
(	I-P
10	I-P
women	I-P
and	I-P
6	I-P
men	I-P
)	I-P
with	I-P
a	I-P
mean	I-P
age	I-P
of	I-P
35	I-P
years	I-P
(	I-P
ranging	I-P
from	I-P
21	I-P
to	I-P
49	I-P
years	I-P
old	I-P
)	I-P
were	O
treated	O
from	O
2004	O
to	O
2005	O
for	O
single	B-I
-	I-I
tooth	I-I
replacement	I-I
in	O
the	O
upper	O
arch	O
.	O

The	O
patients	O
were	O
randomly	O
divided	O
into	O
two	O
groups	O
:	O
in	O
the	O
test	O
group	O
patients	O
received	O
implants	B-I
placed	I-I
and	I-I
restored	I-I
(	I-I
non	I-I
-	I-I
occlusal	I-I
loading	I-I
)	I-I
at	I-I
the	I-I
time	I-I
of	I-I
tooth	I-I
extraction	I-I
;	O
in	O
the	O
control	O
group	O
implants	B-C
were	I-C
placed	I-C
8	I-C
weeks	I-C
after	I-C
tooth	I-C
extraction	I-C
and	I-C
immediately	I-C
restored	I-C
.	O

All	O
the	O
patients	O
received	O
tapered	B-I
effect	I-I
(	I-I
TE	I-I
)	I-I
implants	I-I
from	I-I
the	I-I
Straumann	I-I
Dental	I-I
Implant	I-I
System	I-I
.	O

The	O
following	O
parameters	O
were	O
evaluated	O
at	O
the	O
moment	O
of	O
provisional	O
restoration	O
(	O
within	O
48	O
h	O
after	O
implant	O
placement	O
)	O
and	O
at	O
the	O
2	O
years	O
follow	O
-	O
up	O
visit	O
:	O
marginal	B-O
bone	I-O
resorption	I-O
,	O
papilla	B-O
index	I-O
,	O
position	B-O
of	I-O
the	I-O
mucosal	I-O
margin	I-O
.	O

The	B-O
implant	I-O
stability	I-O
quotient	I-O
was	O
measured	O
at	O
the	B-O
moment	I-O
of	I-O
implant	I-O
placement	I-O
and	O
at	O
the	B-O
moment	I-O
of	I-O
the	I-O
delivery	I-O
of	I-O
the	I-O
definitive	I-O
restoration	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Maintenance	O
of	O
response	O
following	O
stabilization	O
of	O
mixed	O
index	O
episodes	O
with	O
olanzapine	B-I
monotherapy	I-I
in	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
of	O
bipolar	O
1	O
disorder	O
.	O

METHODS	O
:	O
Post	O
-	O
hoc	O
analyses	O
were	O
conducted	O
on	O
data	O
from	O
patients	B-P
presenting	I-P
with	I-P
a	I-P
mixed	I-P
index	I-P
episode	I-P
who	O
were	O
enrolled	O
in	O
a	O
larger	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
.	O

Patients	O
who	O
met	O
remission	O
criteria	O
at	O
2	O
consecutive	O
weekly	O
visits	O
during	O
6	O
to	O
12	O
weeks	O
of	O
open	O
-	O
label	O
olanzapine	O
treatment	O
were	O
randomly	O
assigned	O
to	O
olanzapine	B-I
or	O
placebo	B-C
treatment	O
for	O
48	O
weeks	O
.	O

The	B-O
incidence	I-O
of	I-O
and	O
time	B-O
to	I-O
symptomatic	I-O
relapse	I-O
were	O
calculated	O
for	O
any	B-O
mood	I-O
episode	I-O
,	O
and	O
for	O
depressive	B-O
,	O
manic	B-O
,	O
hypo	B-O
-	I-O
manic	I-O
,	O
and	O
mixed	B-O
mood	I-O
episodes	I-O
.	O

